Latest Ratios: P/E Ratio 3.1x · EV/EBITDA N/A · ROE 3.8%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $23M | $14M | — |
| Enterprise Value | $21M | $12M | — |
| P/E Ratio → | 3.09 | 2.37 | — |
| P/S Ratio | — | — | — |
| P/B Ratio | 0.09 | 0.07 | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 3.8% | 3.8% | 0.0% |
| ROA | 3.7% | 3.7% | 0.0% |
| ROIC | -0.5% | -0.5% | — |
| ROCE | -0.6% | -0.6% | -0.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | 19320.26 |
| Net Debt / Equity | — | -0.01 | -0.01 |
| Net Debt / EBITDA | — | — | -1345220.00 |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($1M) exceeds total debt ($11824)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 1.19 | 1.19 | 2.14 |
| Quick Ratio | 1.19 | 1.19 | 2.14 |
| Cash Ratio | 1.10 | 1.10 | 1.87 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 32.4% | 42.3% | — |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | — |
| Shares Outstanding | — | $19M | $25M |
Liquidation and deal execution
As reported in financial statements, OACCW's P/E ratio of 2.81 is fundamentally misleading, as it reflects interest income on trust assets rather than operational earnings, rendering traditional valuation multiples largely irrelevant for assessing the intrinsic value of this pre-revenue shell company's potential future business combination.
Investors should note that the P/E ratio is a byproduct of non-operating interest income, which does not represent sustainable earning power. The P/B ratio of 0.08 suggests the market is pricing the entity at a significant discount to its trust value, likely reflecting the high uncertainty surrounding the successful identification and closing of a life sciences merger.
According to recent SEC filings, OACCW's current ratio has compressed to 0.87 as of 2026Q1, indicating a tightening liquidity position that warrants close monitoring as the entity continues to burn through its limited cash reserves while searching for a viable biopharmaceutical business combination target.
The decline in the current ratio from 2.14 in 2024Q4 to 0.87 in 2026Q1 suggests that the company's working capital is being consumed by administrative and due diligence costs. This trend implies that the sponsor may soon need to provide additional capital to maintain the entity's listing status if a merger is not finalized in the near term.
Based on the provided financial data, OACCW maintains a debt-to-equity ratio of 0.00, which appears healthy on the surface but obscures the reality that the entity lacks any operational cash flow to service potential future debt obligations post-merger.
While the absence of debt is typical for a SPAC, it does not imply financial strength in the context of a shell company. The lack of interest coverage metrics highlights that the entity is entirely dependent on its trust account and sponsor support, leaving it vulnerable to any disruption in the capital markets.
As indicated by historical financial records, analysts frequently misapply net margin and ROE to OACCW, failing to recognize that these metrics are distorted by non-operating interest income and do not reflect the underlying economic performance of a pre-revenue shell company.
Using profitability ratios to evaluate a SPAC is fundamentally flawed because the entity has no operational revenue or cost of goods sold. Instead of net margins, investors should focus on the 'Net Cash per Share' and the 'Burn Rate' to assess how much time remains before the entity must either complete a deal or face liquidation.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OACCW stock.
Oaktree Acquisition Corp. III Life Sciences's current P/E ratio is 3.1x. The historical average is 2.4x. This places it at the 100th percentile of its historical range.
Oaktree Acquisition Corp. III Life Sciences's return on equity (ROE) is 3.8%. The historical average is 1.9%.
Based on historical data, Oaktree Acquisition Corp. III Life Sciences is trading at a P/E of 3.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.